Polyethylene glycol (PEG) veterinary API is an addition polymer prepared from ethylene oxide and water or ethylene glycol, CAS 25322-68-3, with the general formula H(OCH2CH2)nOH and terminal hydroxyl functionality of 2. The product model designation follows average molecular weight: PEG 400, 600, 1450, 3350, 4000, 6000, and 8000. At 20–25 °C, the lower two grades are clear hygroscopic liquids, PEG 1450 is a low-melting waxy solid, and the higher grades are white flakes, granules, or milled powders. The product is intended for veterinary tablets, injections, capsules, powders, granules, premixes, and solutions. Its difference from technical-grade PEG lies in controlled residual ethylene oxide, dioxane, ethylene glycol/diethylene glycol impurities, peroxide value, and for parenteral grades, bacterial endotoxin and bioburden documentation.

Pharmacopoeial release for this API is anchored to the USP-NF Polyethylene Glycol monograph and the Ph. Eur. Macrogol monograph. Average molecular weight is assigned by combining viscosity at 100 °C according to USP <911> / Ph. Eur. 2.2.9 with hydroxyl value according to Ph. Eur. 2.5.3. The paired measurements constrain molecular-weight distribution more tightly than viscosity alone because they relate terminal hydroxyl groups to oligomer backbone length. Water content is determined by Karl Fischer titration using USP <921>; typical upper limits are 2.0% for solid grades such as PEG 3350 and above, while liquid injection-grade batches can be dried to 0.2% or lower when specified. The API does not contain preservatives, buffers, or surfactant components; downstream formulation therefore requires site-specific blending, filtration, and microbial controls.

How Does the Number-Average Molecular Weight Window Affect Route-Specific Selection?

Route-specific selection is controlled by melt temperature, melt viscosity, water activity, and the mechanical strength of the solidified matrix. Liquid grades are water-miscible and form clear solutions with many organic solvents; solid grades crystallize on cooling and can create fused matrices or granule bridges. Table 1 lists representative compendial grade windows. These values are batch-acceptance ranges rather than single lot averages. Viscosity is measured at 100 °C to provide comparative melt-viscosity profiles above the melting range of the solid grades.

PEG 400 is generally preferred for injectable solutions because it remains filterable at ambient temperature. PEG 600 increases melt and solution viscosity and may require preheated filtration. PEG 3350 and 4000 are selected for tablet melt granulation and premix coating because their melting ranges fall below jacket temperatures of 55–65 °C. PEG 6000 and 8000 are harder solid grades used for sustained-release matrices and moisture-resistant granule coatings. Hydroxyl value decreases as molecular weight increases, reducing terminal-group reactivity and equilibrium moisture sorption per unit mass.

When PEG 400 Replaces Non-Aqueous Carriers in Veterinary Injections

In injectable formulations, PEG 400 is evaluated as a water-miscible non-aqueous vehicle for actives with low aqueous solubility. The compendial pH of a 1 in 20 solution is controlled at 4.5–7.5 using USP <791>. Water content must be specified because residual water can initiate hydrolytic degradation of reconstituted actives. The material is non-ionic and does not introduce the ionic-strength effects typical of buffer salts, but solution viscosity increases non-linearly with concentration. Filtration through 0.22 µm PVDF or PES membranes is used after bulk mixing; filterability declines when formulation viscosity exceeds approximately 150–200 mPa·s at filtration temperature. For parenteral products, batch release includes bacterial endotoxin testing according to Ph. Eur. 5.1.10 and bioburden monitoring in ISO 14644 classified areas. The low water activity of PEG 400 reduces hydrolysis but does not eliminate reactions with nucleophilic actives because the terminal hydroxyl groups remain available. Strong oxidizing agents, certain phenothiazine derivatives, and transition-metal ions can promote oxidative degradation; compatibility screening under ICH Q1A(R2) storage conditions is therefore required before formulation lock.

Published solubility data for specific veterinary active substances in PEG-only vehicles is limited. Each drug candidate requires ternary phase and forced-degradation data rather than direct extrapolation from human pharmaceutical models. Table 2 presents a representative release-test matrix for oral and parenteral veterinary-grade PEG API.

Residual ethylene oxide and dioxane are controlled by gas chromatography to ≤1 ppm and ≤10 ppm, respectively. This is a critical difference from technical PEG used in industrial lubricants and coatings. Food-grade E1521 material may satisfy some chemical limits but is not usually released with the same residual solvent, peroxide, and endotoxin documentation required for veterinary API use.

Direct-compression and melt-granulation applications for veterinary tablets use PEG 4000 or 6000 as a low-melting binder that permits water-free granulation. In a jacketed high-shear mixer, the PEG is added as a molten phase at product temperature 55–65 °C, wetting drug and excipient surfaces within 2–5 min. Cooling below the melting range solidifies binder bridges. Tablet tensile strength is controlled by the PEG fraction and cooling rate, not by water content; residual moisture can remain below 1.0% for hydrolytically unstable actives. When the solid PEG fraction exceeds 8% of the formulation, granule coalescence may produce oversized agglomerates and disintegration time can increase beyond 30 min in USP <701> apparatus. For hard capsules, PEG 400 and 600 are used as water-free fill vehicles for low-melting actives; gelatin shell embrittlement is monitored by equilibrium relative humidity and plasticizer content because PEG can abstract bound water from gelatin at low water activity.

Premix Adsorption, Segregation, and Moisture Uptake in Feed-Mill Manufacturing

In medicated premixes and granulated oral powders, PEG 3350 and 4000 are employed as dust-suppression binders and particle coatings. Milled material with a particle size of 75–250 µm is blended at inclusion rates of 0.5–5.0% w/w to reduce airborne fines and improve flow. Bulk and tapped density are measured by USP <616>; particle-size mismatch between the active and PEG carrier greater than 100 µm leads to segregation in gravity-flow hoppers and content uniformity drift. Steam pelleting at 65–75 °C softens the PEG sufficiently to form bridges, but the same thermal input can create die-face fusion and hardened pellets when post-mixer moisture exceeds 12%. Moisture uptake is reversible but rapid above 60% relative humidity; in unlined fibre drums, caking can occur within 48 h at room temperature. Primary packaging with a moisture vapour transmission rate below 0.1 g/m²/day at 25 °C and 75% RH is specified for tropical distribution.

What Limits the Use of Solid PEG Grades in Capsule Fill and Melt-Coated Granules?

For melt-coated granules, the limiting parameter is solidification window. PEG 3350 has a melting range of 53–57 °C; if coating temperature exceeds 65 °C for more than 10 min, melt viscosity falls below approximately 50 mPa·s and the coating becomes too thin, exposing drug to atmospheric moisture. Rapid cooling creates internal stress and surface crazing, increasing friability and breaking the diffusion barrier. In capsule filling, PEG 400 cannot be used alone as a thermosetting matrix because it remains fluid at room temperature, whereas PEG 6000 can be filled as a melt at 65 °C and allowed to solidify in the capsule shell. The maximum fill viscosity compatible with positive-displacement capsule machines is typically 1,000 mPa·s; above this value, fill-weight variation increases and the product may not meet USP <905> uniformity criteria.

For oral solutions, PEG 400 or 600 is used as a co-solvent and viscosity-modifying carrier. Aqueous formulations containing 20–40% v/v PEG 400 can increase the apparent solubility of weakly acidic and neutral actives without adding surface-active agents. Above 40% v/v, osmotic activity becomes significant in monogastric target species and can produce loose stool or laxation when the total dose is not controlled. Density at 25 °C for PEG 400 is approximately 1.12 g/mL, and viscosity at 25 °C is approximately 90–120 mPa·s. For oral dosage forms, microbial quality is controlled by total aerobic microbial count and specified absence of Escherichia coli and Salmonella according to compendial tests. Preservative efficacy of the finished solution must still be evaluated because PEG can reduce the aqueous activity of some phenolic preservatives.

Stability Boundaries for Autoxidation and Peroxide-Sensitive Actives

PEG undergoes autoxidation at elevated temperature and in the presence of trace photoinitiators or transition metals. Peroxide content is a batch-release parameter when the PEG will be used with oxidation-sensitive actives such as unsaturated fatty acid derivatives, certain macrocyclic lactones, and phenolic antioxidants. Bulk storage in stainless steel or high-density polyethylene containers under nitrogen blanketing is recommended; oxygen headspace should remain below 5% v/v. In unopened containers, low-peroxide grades are controlled to not more than 5 ppm; after opening, material is retested before use because autocatalytic peroxide formation accelerates. Aldehyde and formic acid degradation products are measured because they can react with amine-containing actives, forming imines and esters. Avoid combining PEG with strong oxidizing agents, copper or cobalt salts, and acid-sensitive actives unless forced-degradation data support the combination. The material should not be processed in unpassivated carbon-steel equipment for prolonged hold times, because iron residues promote discoloration and increase peroxide generation.